Global Dry Eye Syndrome Drugs Market 2017-2021

  • ID: 4417848
  • Report
  • Region: Global
  • 88 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Aerie Pharmaceutical
  • Allergan
  • Johnson & Johnson
  • MIMETOGEN
  • Otsuka Holdings
  • Santen Pharmaceutical
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Dry Eye Syndrome Drugs

Dry eye syndrome, also known as keratoconjunctivitis sicca, is the condition of having dry eyes where either the eyes are not capable of producing sufficient tears to maintain lubrication or the when produced, they evaporate too quickly. The condition can lead to various difficulties in the daily life of a person, such as reading for an extended period of time or using a computer. The condition can decrease the tolerance of a person in a dry environment such as air present inside an airplane.

The analysts forecast the global dry eye syndrome drugs market to grow at a CAGR of 7.59% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global dry eye syndrome drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Dry Eye Syndrome Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Novartis
  • Otsuka Holdings
  • Santen Pharmaceutical
Other prominent vendors
  • Aerie Pharmaceutical
  • Akorn
  • Bausch & Lomb
  • Johnson & Johnson
  • Merck
  • MIMETOGEN
  • ReGenTree
  • Sun Pharmaceutical
  • Teva Pharmaceutical
Market drivers
  • Untapped potential in developing countries
  • For a full, detailed list, view the full report
Market challenges
  • Lack of ophthalmology experts
  • For a full, detailed list, view the full report
Market trends
  • Initiatives and programs for supporting patients with ophthalmic disorders
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aerie Pharmaceutical
  • Allergan
  • Johnson & Johnson
  • MIMETOGEN
  • Otsuka Holdings
  • Santen Pharmaceutical
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: MARKET LANDSCAPE
  • Five forces analysis
PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY PRODUCT
  • OTC drugs
  • Prescription drugs
PART 08: REGIONAL LANDSCAPE
  • Regional comparison
  • Dry eye syndrome drugs market in Americas
  • Dry eye syndrome drugs market in EMEA
  • Dry eye syndrome drugs market in APAC
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Initiatives and programs for supporting patients with ophthalmic disorders
  • Advancement in diagnostic techniques for dry eye syndrome
PART 12: VENDOR LANDSCAPE

PART 13: KEY VENDOR ANALYSIS
  • Allergan
  • Otsuka Holdings
  • Novartis
  • Santen Pharmaceutical
  • Other prominent vendors
PART 14: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Market share of ophthalmic drugs market 2016
Exhibit 02: Causes of dry eyes
Exhibit 03: Symptoms, diagnosis, and treatment of dry eyes
Exhibit 04: Dry eye syndrome drugs market: Snapshot
Exhibit 05: Global dry eye syndrome drugs market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline molecules in Phase III by vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global dry eye syndrome drugs market by product 2016-2021 (% share)
Exhibit 10: Global dry eye syndrome drugs market by OTC drugs 2016-2021 ($ millions)
Exhibit 11: Qualities of OTC drugs present in the market
Exhibit 12: OTC drugs based on inclusion of preservatives
Exhibit 13: Global dry eye syndrome drugs market by prescription drugs 2016-2021 ($ millions)
Exhibit 14: Regional landscape
Exhibit 15: Regional comparison
Exhibit 16: Dry eye syndrome drugs market in Americas 2016-2021 ($ millions)
Exhibit 17: Dry eye syndrome drugs market in Americas - Year over year growth
Exhibit 18: Dry eye syndrome drugs market in EMEA 2016-2021 ($ millions)
Exhibit 19: Dry eye syndrome drugs market in EMEA - Year over year growth
Exhibit 20: Dry eye syndrome drugs market in APAC 2016-2021 ($ millions)
Exhibit 21: Dry eye syndrome drugs market in APAC - Year over year growth
Exhibit 22: Key leading countries
Exhibit 23: World population by age group: 2015-2050
Exhibit 24: Percentage of population aged 60 and above by region 2015-2050
Exhibit 25: Risk factors for developing dry eye syndrome in older population
Exhibit 26: Demographic and economic snapshot of India and China
Exhibit 27: Factors causing autoimmune disorders
Exhibit 28: Top concerns of health insurance in US
Exhibit 29: Competitive structure analysis of global dry eye syndrome drugs market 2016
Exhibit 30: Vendor landscape for global dry eye syndrome drugs market 2016-2021
Exhibit 31: Allergan: Key highlights
Exhibit 32: Allergan: Strength assessment
Exhibit 33: Allergan: Strategy assessment
Exhibit 34: Allergan: Opportunity assessment
Exhibit 35: Otsuka Holdings: Key highlights
Exhibit 36: Otsuka Holdings: Strength assessment
Exhibit 37: Otsuka Holdings: Strategy assessment
Exhibit 38: Otsuka Holdings: Opportunity assessment
Exhibit 39: Novartis: Key highlights
Exhibit 40: Novartis: Strength assessment
Exhibit 41: Novartis: Strategy assessment
Exhibit 42: Novartis: Opportunity assessment
Exhibit 43: Santen Pharmaceutical: Key highlights
Exhibit 44: Santen Pharmaceutical: Strength assessment
Exhibit 45: Santen Pharmaceutical: Strategy assessment
Exhibit 46: Santen Pharmaceutical: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Aerie Pharmaceutical
  • Allergan
  • Johnson & Johnson
  • MIMETOGEN
  • Otsuka Holdings
  • Santen Pharmaceutical
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: - Global Dry Eye Syndrome Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global dry eye syndrome drugs market: Allergan, Novartis, Otsuka Holdings, and Santen Pharmaceutical.

Other Prominent Vendors in the market are: Aerie Pharmaceutical, Akorn, Bausch & Lomb, Johnson & Johnson, Merck, MIMETOGEN, ReGenTree, Sun Pharmaceutical, and Teva Pharmaceutical.

Commenting on the report, an analyst from the research team said: “One trend in the market is Initiatives and programs for supporting patients with ophthalmic disorders. Public awareness about problems related to visual impairment has increased in the last decade because of the increase in the number of government initiatives undertaken by various organizations.”

According to the report, one driver in the market is untapped potential in developing countries. Countries such as India, China, and Brazil are some of the most attractive countries for pharmaceutical companies globally. Several factors are responsible for the high growth of the healthcare sector in developing countries. Vast population, growing geriatric population, and lifestyle disorders such as obesity and diabetes that lead to dry eye syndrome are factors expected to drive the market in developing countries.

Further, the report states that one challenge in the market is lack of ophthalmology experts. The lack of trained ophthalmologists who have expertise in treating eye disorders such as dry eyes is one of the key challenges in the market. Although the number of people diagnosed with or prone to eyesight disorders has been on the rise, there are insufficient trained and experienced eye care professionals (ophthalmologists, optometrists, ophthalmic assistants, and ophthalmic nurses) to treat eye disorders. For instance, in Europe, there is just one ophthalmologist for every 8,000 individuals.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

  • Allergan
  • Novartis
  • Otsuka Holdings
  • Santen Pharmaceutical
  • Aerie Pharmaceutical
  • Akorn
  • Bausch & Lomb
  • Johnson & Johnson
  • Merck
  • MIMETOGEN
  • ReGenTree
  • Sun Pharmaceutical
  • Teva Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll